Download
Shineco (NASDAQ: SISI) announced that its subsidiary InfiniClone, in which it holds a 51% stake, has entered into a strategic distribution agreement with Total World Marketing (TWM) to expand into Southeast Asia’s healthcare market. InfiniClone will offer two main product lines: molecular detection kits based on iPSC technology for analyzing genetic mutations and diseases, and Purelix health products for customized immune enhancement and health solutions. TWM has begun pilot sales of Purelix products in Thai supermarkets and plans to expand to pharmacies, clinics, and e-commerce platforms once FDA approval is obtained for the molecular detection kits. The Southeast Asian healthcare market shows strong growth potential, with e-commerce platforms Shopee and Lazada reporting $1.57 billion in healthcare product sales in 2023, marking a 25% year-over-year increase.
Shineco (NASDAQ: SISI) ha annunciato che la sua controllata InfiniClone, di cui detiene una quota del 51%, ha siglato un accordo strategico di distribuzione con Total World Marketing (TWM) per espandersi nel mercato sanitario del Sud-est asiatico. InfiniClone offrirà due linee di prodotti principali: kit di rilevazione molecolare basati sulla tecnologia iPSC per l’analisi di mutazioni genetiche e malattie, e prodotti per la salute Purelix per il potenziamento immunitario personalizzato e soluzioni di benessere. TWM ha avviato le vendite pilota dei prodotti Purelix nei supermercati thailandesi e prevede di espandersi in farmacie, cliniche e piattaforme di e-commerce una volta ottenuta l’approvazione FDA per i kit di rilevazione molecolare. Il mercato sanitario del Sud-est asiatico mostra un forte potenziale di crescita, con le piattaforme di e-commerce Shopee e Lazada che hanno registrato 1,57 miliardi di dollari di vendite di prodotti sanitari nel 2023, segnando un incremento del 25% rispetto all’anno precedente.
Shineco (NASDAQ: SISI) anunció que su subsidiaria InfiniClone, en la que posee una participación del 51%, ha firmado un acuerdo estratégico de distribución con Total World Marketing (TWM) para expandirse en el mercado de salud del sudeste asiático. InfiniClone ofrecerá dos líneas principales de productos: kits de detección molecular basados en tecnología iPSC para analizar mutaciones genéticas y enfermedades, y productos de salud Purelix para el fortalecimiento inmune personalizado y soluciones de bienestar. TWM ha iniciado ventas piloto de productos Purelix en supermercados tailandeses y planea expandirse a farmacias, clínicas y plataformas de comercio electrónico una vez que se obtenga la aprobación de la FDA para los kits de detección molecular. El mercado de salud del sudeste asiático muestra un fuerte potencial de crecimiento, con las plataformas de comercio electrónico Shopee y Lazada reportando 1.570 millones de dólares en ventas de productos de salud en 2023, marcando un aumento interanual del 25%.
Shineco(NASDAQ: SISI)는 지분 51%를 보유한 자회사 InfiniClone이 Total World Marketing(TWM)과 전략적 유통 계약을 체결하여 동남아시아 헬스케어 시장에 진출한다고 발표했습니다. InfiniClone은 유전자 변이 및 질병 분석을 위한 iPSC 기술 기반 분자 검출 키트와 맞춤형 면역 강화 및 건강 솔루션을 위한 Purelix 건강 제품 두 가지 주요 제품 라인을 제공합니다. TWM은 태국 슈퍼마켓에서 Purelix 제품의 시범 판매를 시작했으며, 분자 검출 키트에 대한 FDA 승인이 완료되면 약국, 클리닉, 전자상거래 플랫폼으로 확장할 계획입니다. 동남아시아 헬스케어 시장은 강력한 성장 잠재력을 보이고 있으며, 전자상거래 플랫폼 Shopee와 Lazada는 2023년 헬스케어 제품 매출 15억 7천만 달러를 기록하며 전년 대비 25% 증가했습니다.
Shineco (NASDAQ : SISI) a annoncé que sa filiale InfiniClone, dont elle détient 51 % des parts, a conclu un accord stratégique de distribution avec Total World Marketing (TWM) pour s’étendre sur le marché de la santé en Asie du Sud-Est. InfiniClone proposera deux principales gammes de produits : des kits de détection moléculaire basés sur la technologie iPSC pour l’analyse des mutations génétiques et des maladies, ainsi que des produits de santé Purelix pour le renforcement immunitaire personnalisé et des solutions de bien-être. TWM a lancé des ventes pilotes des produits Purelix dans des supermarchés thaïlandais et prévoit de s’étendre aux pharmacies, cliniques et plateformes de commerce électronique une fois l’approbation de la FDA obtenue pour les kits de détection moléculaire. Le marché de la santé en Asie du Sud-Est montre un fort potentiel de croissance, avec les plateformes e-commerce Shopee et Lazada ayant rapporté 1,57 milliard de dollars de ventes de produits de santé en 2023, soit une augmentation de 25 % par rapport à l’année précédente.
Shineco (NASDAQ: SISI) gab bekannt, dass seine Tochtergesellschaft InfiniClone, an der es 51 % beteiligt ist, eine strategische Vertriebsvereinbarung mit Total World Marketing (TWM) eingegangen ist, um in den Gesundheitsmarkt Südostasiens zu expandieren. InfiniClone wird zwei Hauptproduktlinien anbieten: molekulare Nachweiskits auf Basis der iPSC-Technologie zur Analyse genetischer Mutationen und Krankheiten sowie Purelix-Gesundheitsprodukte für maßgeschneiderte Immunverstärkung und Gesundheitslösungen. TWM hat Pilotverkäufe der Purelix-Produkte in thailändischen Supermärkten gestartet und plant, nach Erhalt der FDA-Zulassung für die molekularen Nachweiskits auf Apotheken, Kliniken und E-Commerce-Plattformen zu expandieren. Der Gesundheitsmarkt in Südostasien zeigt starkes Wachstumspotenzial, wobei die E-Commerce-Plattformen Shopee und Lazada im Jahr 2023 einen Umsatz von 1,57 Milliarden US-Dollar mit Gesundheitsprodukten verzeichneten, was einem 25%igen Wachstum gegenüber dem Vorjahr entspricht.
Positive
- Strategic expansion into the growing Southeast Asian healthcare market through TWM’s distribution network
- Access to multiple sales channels including supermarkets, pharmacies, clinics, and e-commerce platforms
- Innovative product offering combining molecular detection kits and personalized health solutions
- Entry into a market with 25% YoY growth in healthcare product sales
- Potential for additional partnerships with medical institutions for clinical applications
Negative
- Pending regulatory approval from Thai FDA for molecular detection kits
- Initial market penetration limited to supermarket channels
- Success dependent on market acceptance of new technology and products
Insights
Shineco expands into Southeast Asia through InfiniClone’s partnership with TWM, targeting the fast-growing $1.57B healthcare market with diagnostic and supplement products.
Shineco’s newly acquired subsidiary InfiniClone (51% stake acquired April 25) has secured a strategic distribution agreement with Total World Marketing for Southeast Asian market entry. This partnership will distribute InfiniClone’s molecular detection kits and Purelix health products across the region, where healthcare product sales reached
InfiniClone’s technology offering creates a compelling integrated health solution. Their molecular detection kits utilize proprietary iPSC (induced pluripotent stem cell) technology to analyze genetic mutations for diseases including diabetes, cancer, and Alzheimer’s, along with genetic characteristics affecting drug response and metabolism. The complementary Purelix health products then provide customized supplements based on test results, creating a closed-loop “detection-intervention” system.
The execution strategy shows thoughtful market entry planning. TWM has already begun pilot sales of Purelix products through Thai supermarkets, with planned expansion to pharmacies, clinics, and e-commerce following regulatory approval. InfiniClone is simultaneously negotiating with medical institutions to explore clinical applications for their detection kits.
While the current agreement establishes initial distribution channels, the announcement reveals longer-term ambitions beyond diagnostics and supplements. Dr. Lim Kah Meng’s comments suggest further R&D into tissue repair and anti-aging applications of their iPSC technology, indicating a technology platform with potential multiple commercialization pathways beyond the current products.
BEIJING, May 13, 2025 (GLOBE NEWSWIRE) — Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, today announced that InfiniClone Limited (“InfiniClone”), Shineco’s majority-owned subsidiary in which the Company acquired a
The healthcare consumer market in Southeast Asia is experiencing dynamic growth. As an indicator, Moojing Market Intelligence, a Chinese market research and intelligence firm, states that the sales of healthcare products by Shopee and Lazada, the two major e-commerce platforms in Southeast Asia, reached
InfiniClone’s molecular detection kit is based on its core iPSC technology, and it is designed to analyze genetic mutations for diseases including diabetes, cancer, Alzheimer’s disease, as well as genetic characteristics such as drug response, skin characteristics, and nutritional metabolism; the kit is expected to provide consumers with a firm basis for personalized health management. InfiniClone’s Purelix health products are designed to customize immune enhancement, brain nerve support and antioxidant solutions based on InfiniClone’s molecular detection kit test results, and Purelix dietary supplements can also achieve symptomatic relief. The Company expects the two major product lines to form a “detection-intervention” closed-loop system to help consumers understand their health profiles and help them address certain medical issues.
Dr. Lim Kah Meng, founder of InfiniClone, commented, “The breakthrough application of our iPSC technology serves as the basis for the accuracy of InfiniClone’s two products, and we anticipate TWM’s extensive coverage in supermarket channels will provide a solid foundation for our initial market penetration. Looking forward, we plan to further deepen the coverage dimension of disease risk prediction and explore the application of our iPSC technology in the field of tissue repair and anti-aging to provide more comprehensive health solutions for the Southeast Asian market.”
TWM has currently launched a pilot sale of InfiniClone’s Purelix health products through supermarket channels in Thailand, and it plans to expand next month into multiple sales channels such as pharmacies, clinics and e-commerce platforms after obtaining approval from the Thai Food and Drug Administration for InfiniClone’s molecular detection kits. In addition, InfiniClone is negotiating with a number of medical institutions in Southeast Asia to explore the clinical application of molecular detection kits in early disease screening and treatment monitoring.
Jennifer Zhan, the CEO of Shineco, emphasized, “We believe the recent acquisition of InfiniClone has not only improved our competitive positioning, but it is also helping us to develop an integrated network of ‘R&D-production-distribution’ centered on Southeast Asia. The cooperation between InfiniClone and TWM is being developed in a phased strategy, initially focusing on supermarket channels to obtain market feedback and gradually expanding in conjunction with the progress of regulatory approval.”
“By integrating TWM’s channel resources with InfiniClone’s R&D advantages, we are confident that we will be able to quickly respond to Southeast Asian market demand. We also plan to accelerate the application and transformation of stem cell technology in the field of big health, which encompasses the spectrum of prevention, wellness and technology-driven solutions. InfiniClone’s product line aligns exceptionally well with the high-growth trajectory of big health, a pivotal strategy that we believe will generate considerable benefits for Shineco and create long-term value for our shareholders,” CEO Ms. Zhan concluded.
About InfiniClone
InfiniClone is a biotech company based in Singapore and controlled by Shineco. It is an innovative enterprise focusing on induced pluripotent stem cell (iPSC) technology and regenerative medicine. For more information about InfiniClone, please visit www.infiniclone.com/.
About Shineco, Inc.
Shineco, Inc. (“Shineco” or the “Company”) aims to “focus on healthy living and improve the quality of life” by providing safe, efficient and high-quality health and medical products and services to society. Shineco, operating through subsidiaries, has researched and developed 33 kinds of in vitro diagnostic reagents and related medical devices to date, and the Company also produces and sells healthy and nutritious foods. For more information about Shineco, please visit www.biosisi.com/.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by words such as “may,” “will,” “should,” “could,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “forecast,” “potential,” “continue,” “evaluate” or similar words. Forward-looking statements should not be relied upon as they are neither historical facts nor guarantees of future performance. Rather, they are based solely on our current beliefs, expectations and assumptions about future business, future plans and strategies, forecasts, expected events and trends, economics, and other future conditions. Examples of forward-looking statements include, among other things, our innovation and market position in our products and services, our competitive advantages, and our expectation that the 5-minute cardiac test will be one of the leading products in this field to meet the need for test results immediately upon intake. Please do not rely on any forward-looking statements. Actual results may differ materially from those indicated in historical results or forward-looking statements due to various factors, including, but not limited to, the Company’s ability to raise additional capital, its ability to maintain and grow its business, the variability of its results of operations, its ability to maintain and enhance its brand, its ability to develop and introduce new products and services, its ability to obtain all necessary regulatory approvals in the jurisdictions in which it intends to market and sell its products, Companies to be acquired, Successful integration of technology and assets into its portfolio of products and services Marketing and other business development initiatives Industry competition, general government regulations, economic conditions, impact of the COVID-19 pandemic, reliance on key personnel, attracting, hiring and retaining personnel with the technical skills and experience required to meet customer requirements and protect intellectual property. Shineco encourages you to review other factors that may affect its future performance in its filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based only on information currently available to us and are made only as of the date of this press release, and Shineco undertakes no obligation to update any forward-looking statements, except as required by applicable rules and regulations.
For more information, please contact:
Shineco, Inc.
secretary@shineco.tech
Mobile: +86-010-68130220
Precept Investor Relations LLC
David J. Rudnick
david.rudnick@preceptir.com
Mobile: +1-646-694-8538
FAQ
What is the strategic partnership between Shineco (SISI) and Total World Marketing?
Shineco’s subsidiary InfiniClone has partnered with Total World Marketing for distribution of molecular detection kits and Purelix health products in Southeast Asia, with TWM handling promotion and sales.
What products will Shineco (SISI) distribute in Southeast Asia through this partnership?
Shineco will distribute two main product lines: molecular detection kits based on iPSC technology for genetic analysis, and Purelix health products for immune enhancement and personalized health solutions.
How large is the Southeast Asian healthcare market for Shineco (SISI)?
The Southeast Asian healthcare market shows significant growth, with Shopee and Lazada reporting $1.57 billion in healthcare product sales in 2023, a 25% year-over-year increase.
When will Shineco (SISI) expand its distribution channels in Thailand?
TWM plans to expand distribution to pharmacies, clinics, and e-commerce platforms next month, following Thai FDA approval for InfiniClone’s molecular detection kits.
What is Shineco’s (SISI) ownership stake in InfiniClone?
Shineco acquired a 51% majority equity interest in InfiniClone on April 25, 2025.